FDA grants fast track designation for HAYA Therapeutics’ HTX-001

By targeting WISPER in cardiac myofibroblasts, HTX-001 is intended to facilitate the precise reprogramming of the fibrotic and pathological cell states. Credit: NMK-Studio / Shutterstock.com.



  • FDA HAYA HTX-001